RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FREDIANI F
Collezione ASL Asti

Items : 4

Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17.

2024
ASL Asti

Barbanti P; Aurilia C; Egeo G; Proietti S; D'Onofrio F; Torelli P; Aguggia M; Bertuzzo D; Finocchi C; Trimboli M; Cevoli S; Fiorentini G; Orlando B; Zucco M; Di Clemente L; Cetta I; Colombo B; di Poggio MLB; Favoni V; Grazzi L; Salerno A; Carnevale A; Robotti M; Frediani F; Altamura C; Filippi M; Vernieri F; Bonassi S;

Correction to: Ultra-late response (>?24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. in Journal of neurology / J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3.

2024
ASL Asti

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. in The journal of headache and pain / J Headache Pain. 2023 Mar 23;24(1):30. doi: 10.1186/s10194-023-01561-w.

2023
ASL Asti

Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;

Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2020 Dec;41(Suppl 2):487-488. doi: 10.1007/s10072-020-04669-y.

2020
ASL Asti

Vernieri F; Altamura C; Aurilia C; Brunelli N; Egeo G; Fofi L; Costa CM; Fallacara A; Favoni V; Pierangeli G; Aguggia M; Bertuzzo D; Albanese M; Di Fiore P; Frediani F; Cevoli S; Barbanti P;